Cargando…

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review

Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rationa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gardini, Andrea Casadei, Santini, Daniele, Aprile, Giuseppe, Silvestris, Nicola, Felli, Emanuele, Foschi, Francesco Giuseppe, Ercolani, Giorgio, Marisi, Giorgia, Valgiusti, Martina, Passardi, Alessandro, Puzzoni, Marco, Silletta, Marianna, Brunetti, Oronzo, Cardellino, Giovanni Gerardo, Frassineti, Giovanni Luca, Scartozzi, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630448/ https://www.ncbi.nlm.nih.gov/pubmed/29029548 http://dx.doi.org/10.18632/oncotarget.19449

Ejemplares similares

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival
por: Gardini, Andrea Casadei, et al.
Publicado: (2018)

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
por: Casadei Gardini, Andrea, et al.
Publicado: (2017)

Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials
por: Casadei Gardini, Andrea, et al.
Publicado: (2019)

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
por: Marisi, Giorgia, et al.
Publicado: (2019)

Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018)

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017)

Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin
por: De Matteis, Serena, et al.
Publicado: (2019)

Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study
por: Passardi, Alessandro, et al.
Publicado: (2019)

Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers 2019, 11, 663
por: Passardi, Alessandro, et al.
Publicado: (2020)

Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials
por: Gardini, Andrea Casadei, et al.
Publicado: (2018)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

Immunotherapeutic approaches for hepatocellular carcinoma
por: Longo, Vito, et al.
Publicado: (2017)

Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
por: Ulivi, Paola, et al.
Publicado: (2016)

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2018)

Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
por: Caputo, Francesco, et al.
Publicado: (2020)

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
por: Faloppi, Luca, et al.
Publicado: (2016)

Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial
por: Casadei Gardini, Andrea, et al.
Publicado: (2020)

(1)H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages
por: Casadei-Gardini, Andrea, et al.
Publicado: (2020)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study
por: Solaini, Leonardo, et al.
Publicado: (2019)

Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy
por: Casadei-Gardini, Andrea, et al.
Publicado: (2023)

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
por: Ulivi, Paola, et al.
Publicado: (2012)

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial
por: Passardi, Alessandro, et al.
Publicado: (2017)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

Conversion Surgery in Gastric Cancer Carcinomatosis
por: Morgagni, Paolo, et al.
Publicado: (2022)

Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with locally advanced rectal cancer: a multicenter phase II trial
por: Passardi, Alessandro, et al.
Publicado: (2020)

Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies
por: Passardi, Alessandro, et al.
Publicado: (2021)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
por: Burgio, Valentina, et al.
Publicado: (2021)

Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib
por: Sapena, Víctor, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ig7ju3u0p0ooteiinape1fu747